Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Final decision from the European Commission is anticipated within the coming months
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
CSPC will receive an upfront payment of $100 million from AstraZeneca
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Poor oral health (periodontal disease) impacts nearly 51% of Indians
India has taken the lead in recognising NAFLD as a major non-communicable disease
Subscribe To Our Newsletter & Stay Updated
